Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: A prospective randomized study

Neuroendocrinology

Volumn 96, Issue 4, 2012, Pages 294-300

  Maire, Frédérique ^a   Lombard Bohas, Catherine ^b   O'Toole, Dermot ^a   Vullierme, Marie Pierre ^a   Rebours, Vinciane ^a   Couvelard, Anne ^a   Pelletier, Anne Laure ^a   Zappa, Magaly ^a   Pilleul, Frank ^b   Hentic, Olivia ^a   Hammel, Pascal ^a   Ruszniewski, Philippe ^a  

^a BEAUJON HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Chemoembolization; Embolization; Liver metastases; Midgut endocrine tumors; Progression free survival

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; DOXORUBICIN; IODINATED POPPYSEED OIL; LIPIODOL ULTRA FLUID; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CONTROL; CANCER PATIENT; CARCINOID CRISIS; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE TUMOR; FEMALE; HEPATIC ARTERIAL EMBOLIZATION; HUMAN; INTESTINE TUMOR; LIVER METASTASIS; LIVER RESECTION; MALE; MIDGUT ENDOCRINE TUMOR; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; POSTEMBOLIZATION SYNDROME; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84871618845     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000336941     Document Type: Article

References (31)

1. Plockinger U, Rindi G, Arnold R, et al: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
2. Hentic O, Couvelard A, Rebours V, et al: Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. En-docr Relat Cancer Cancer 2010; 18: 51-59.
3. Norton JA, Warren RS, Kelly MG, et al: Aggressive surgery for metastatic liver neuroendocrine tumors. Surger y 2003; 134: 1057-1063.
4. Sarmiento JM, Heywood G, Rubin J, et al: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.
5. Kianmanesh R, Sauvanet A, Hentic O, et al: Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 2008; 247: 659-665.
6. Jaeck D, Oussoultzoglou E, Rosso E, et al: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. A nn Surg 2004; 240: 1037-1049.
7. Elias D, Goéré D, Leroux G, et al: Combined liver surgery and RFA for patients with gas-troenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009; 35: 1092-1097.
8. O'Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003; 10: 463-468.
9. Moertel CG, Johnson CM, McKusick MA, et al: The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120:302-309.
10. Engstrom PF, Lavin PT, Moertel CG, et al: Streptozocin plus fluorouracil versus doxo-rubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2:1255-1259.
11. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
12. Pavel ME, Hainsworth JD, Baudin E, et al: RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-control led, phase 3 study. Lancet 2011; 378: 2005-2012.
13. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90:220-226.
14. Ruszniewski P, Rougier P, Roche A, et al: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Ca ncer 1993; 71: 2624-2630.
15. Marrache F, Vullierme MP, Roy C, et al: Arterial phase enhancement and body mass index are predictors of response to chemoem-bolisation for liver metastases of endocrine tumours. Br J Cancer 2007; 96:49-55.
16. Dominguez S, Denys A, Madeira I, et al: Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastro-enterol Hepatol 2000; 12:151-157.
17. Roche A, Girish BV, de Baere T, et al: Trans-catheter arterial chemoembolization as firstline treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13: 136-140.
18. Diaco DS, Hajarizadeh H, Mueller CR, et al: Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995; 169:523-528.
19. Gupta S, Johnson MM, Murthy R, et al: Hepatic arterial embolization and chemoembo-lization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590-1602.
20. Kloppel G, Perren A, Heitz PU: The gastro-enteropancreatic neuroendocrine cell system and its tumors: the WHO classification. A nn N Y Acad Sci 2004; 1014: 13-27.
21. Strosberg JR, Choi J, Cantor AB, et al: Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13: 72-78.
22. Osborne DA, Zervos EE, Strosberg J, et al: Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572-581.
23. Bloomston M, Al-Saif O, Klemanski D, et al: Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 2007; 11: 264-271.
24. Ho AS, Picus J, Darcy MD, et al: Long-term outcome after chemoembolization and em-bolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol 2007; 188: 1201-1207.
25. Kamat PP, Gupta S, Ensor JE, et al: Hepatic arterial embolization and chemoemboliza-tion in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol 2008; 31:299-307.
26. Swärd C, Johanson V, Nieveen van Dijkum E, et al: Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96:517-521.
27. Artinyan A, Nelson R, Soriano P, et al: Treatment response to transcatheter arterial em-bolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Ox ford) 2008; 10: 396-404.
28. Christante D, Pommier S, Givi B, et al: Hepatic artery chemoinfusion with chemoem-bolization for neuroendocrine cancer with progressive hepatic metastases despite oc-treotide therapy. Surgery 2008; 144:885-894.
29. Brown DB, Pilgram TK, Darcy MD, et al: Hepatic arterial chemoembolization for hepa-tocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661-1666.
30. Ruutiainen AT, Soulen MC, Tuite CM, et al: Chemoembolization and bland emboliza-tion of neuroendocrine tumor metastases to the liver. Vasc Interv Radiol 2007; 18: 847-855.
31. de Baere T, Deschamps F, Teriitheau C, et al: Transarterial chemoembolization of liver metastases from well differentiated gastro-enteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Inter v Radiol 2008; 19: 855-861.